“Update your knowledge of new medications used in the management of diabetes”
This presentation will discuss what’s new in medications to manage glycaemia for people living with diabetes.
We will discuss new insulins: Ryzodeg, Fiasp, Optisulin and Semglee; confer what biosimilarity signifies in insulins. Dulaglutide and Semaglutide are ground-breaking new GLP-1 therapies to highlight.
We finish with an update on post-market evidence around SGLT-2 inhibitors and its latest member Ertugliflozin.
In this session you will:
- Update your knowledge of new medications used in the management of diabetes
- Explore the new insulins Ryzodeg, Fiasp, Optisulin and Semglee
- Understand the concept of biosimilarity in biological medications such as insulins
- Become familiar with new GLP-1 agonists and their use and understand the new evidence for SGLT-2 inhibitors and use this in practice
BPharm, MPS, AACPA, CDE
Donna studied Pharmacy at the University of Queensland and has been a community Pharmacist for over 30 years. She attended further study to become accredited to perform medication reviews with the Australian Consultant Pharmacist Association (AACPA). In her work as a Pharmacist, a significant portion of her clients live with diabetes. This motivated her to study Diabetes education at the Southern Cross University on the Gold Coast and graduate in 2016…Read More>>